Browse EX-10 agreements

AMENDED AND RESTATED EXECUTIVE OFFICER SEVERANCE AGREEMENT

THIS AMENDED AND RESTATED EXECUTIVE OFFICER SEVERANCE AGREEMENT (“Agreement”) made and entered into as of the 23rd day of February 2026, by and between HELIOS TECHNOLOGIES, INC., a Florida corporation, along with its affiliates and subsidiaries (together, the “Company”) and Sean P. Bagan (“Executive”) amends and restates in its entirety the previous CEO Executive Officer Severance Agreement made and entered into as of the 6th day of January 2025 by and between Company and Executive.

W I T N E S S E TH:

WHEREAS, Executive is the President and Chief Executive Officer of the Company; and

WHEREAS, the Company wishes to provide amended and restated severance benefits to Executive in the event of an involuntary termination of Executive’s employment, as specified herein;

NOW, THEREFORE, in consideration of the foregoing recitals and the agreements of the parties contained herein, the parties do hereby agree as follows:

…

Manulife Private Credit Fund

SUBADVISORY AGREEMENT

This AGREEMENT (this “Agreement”) is made as of this 1st day of March, 2026 (the “Effective Date”), by and between Manulife Investment Management Private Markets (US) LLC, a Delaware limited liability company (the “Adviser”), and Comvest Credit Advisors LLC, a Delaware limited liability company (the “Subadviser”). In consideration of the mutual covenants contained herein, the parties agree as follows:

1.	APPOINTMENT OF SUBADVISER

…

---

Exhibit 10.1

FIRST BANCORP

2026 OMNIBUS INCENTIVE PLAN

Section I

PURPOSE

The purpose of the First BanCorp 2026 Omnibus Incentive Plan, as it may be amended from time to time (the “Plan”), is to promote the interests of the Corporation and its stockholders by delivering long term incentive compensation benefits to the Corporation’s and its Affiliates’ employees and directors, who are expected to contribute significantly to the success of the Corporation and its Affiliates.  These benefits provide a proprietary interest in the continued growth and success of the Corporation through the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. The Plan is also intended to encourage recipients to remain in the employ or service of the Corporation and its Affiliates and to assist the Board and management in the attraction and recruitment of qualified service providers to serve the

…

AMENDED AND RESTATED LICENSE AGREEMENT

THIS AMENDED AND RESTATED LICENSE AGREEMENT (“Agreement”) is made and entered into as of April 30, 2026 (“Effective Date”), by and between SEKISUI HOUSE, LTD., a Japanese public company with its principal place of business at 1-1-88, Oyodonaka, Kita-ku, Osaka, 531-0076, JAPAN (“Licensor”), and Sekisui House U.S., Inc., a Delaware corporation with its principal place of business at 4350 South Monaco Drive, Denver, CO 80237, USA (“Licensee”).

BACKGROUND

WHEREAS, Licensor indirectly owns 100% of the equity interests in Licensee;

WHEREAS, Licensee is engaged, both directly and indirectly through subsidiaries, in the business of conducting certain homebuilding activities in the USA;

…

FIRST AMENDMENT TO THE

SEKISUI HOUSE U.S., INC.

(formerly known as M.D.C. Holdings, Inc.)

LONG TERM INCENTIVE PLAN

This First Amendment (the “First Amendment”) amends the M.D.C. Holdings, Inc. Long Term Incentive Plan, approved January 30, 2025, with an Effective Date of January 1, 2025 (the “Plan”). All capitalized terms not defined herein shall have the meaning defined in the Plan.

RECITALS

M.D.C. Holdings, Inc. changed its legal name to Sekisui House U.S., Inc., on or about September 4, 2025.

Section 8(d) of the Plan permits the Plan to be amended as provided therein. The Company has determined that it is beneficial to amend the Plan to be effective for all Long Term Incentive Awards that are granted on or after January 1, 2026.

AMENDMENT

The Plan is hereby amended as follows:

1.The name of the Plan is the “Sekisui House U.S., Inc. Long Term Incentive Plan.”

2.All references to “M.D.C. Holdings, Inc.” in the Plan are hereby replaced with “Sekisui House U.S., Inc.”

3.Section 5(b) of the Plan document is hereby amended and fully replaced with the following:

…

Employee Form Exhibit 10.2

DAMORA THERAPEUTICS, INC.

2026 EQUITY INCENTIVE PLAN

GRANT NOTICE FOR STOCK OPTIONS

FOR GOOD AND VALUABLE CONSIDERATION, Damora Therapeutics, Inc. (the “Company”), hereby grants to Participant named below an option (the “Option”) to purchase any part or all of the number of Common Stock that are covered by this Option at the Exercise Price per share, each specified below, and upon the terms and subject to the conditions set forth in this Grant Notice, the Damora Therapeutics, Inc. 2026 Equity Incentive Plan (as amended from time to time, the “Plan”), and the Standard Terms and Conditions (the “Standard Terms and Conditions”) promulgated under such Plan and attached hereto as Exhibit A. This Option is granted pursuant to the Plan and is subject to and qualified in its entirety by the Standard Terms and Conditions. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan.

…

April 13, 2026

Jonathan Siegler

Dear Mr. Siegler,

DIRECTOR SERVICES APPOINTMENT AS A NON-EXECUTIVE DIRECTOR OF 5E ADVANCED MATERIALS, INC.

We are pleased and welcome your acceptance to be appointed as a Non-Executive Director (“NED”) of 5E Advanced Materials, Inc. (the “Company”), a company incorporated under the laws of the State of Delaware.

The following letter seeks to illustrate the context of your appointment by the Company, and the terms and conditions of such appointment, as set out herewith. It is agreed that on acceptance of this offer, this letter will constitute a contract for services and not a contract of employment.

…

RECIPROCAL LOAN AGREEMENT

This RECIPROCAL LOAN AGREEMENT (this “Agreement”), dated as of April 1, 2026, between Voya Retirement Insurance and Annuity Company, a Connecticut life insurance company (“VRIAC” or “Company”), located at One Orange Way, Windsor, Connecticut 06095 and Voya Financial, Inc., a Delaware corporation (“Voya Financial” or “Company”), located at 200 Park Avenue, New York, New York 10166 (collectively referred to as the "Companies").

WITNESSETH:

WHEREAS, each of the Companies may have, from time to time, a need to borrow funds on a revolving basis; and

WHEREAS, each of the Companies may have, from time to time, excess cash available to lend to the other on a revolving basis; and

WHEREAS, the Companies are affiliated entities and as such are willing to extend financing to, and borrow from each other as provided herein; and

WHEREAS, each of the Companies desires to enter into this Agreement providing for, among other things, the making of such Loans by and among each other;

…

SOLID BIOSCIENCES INC.

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

The non-employee directors of Solid Biosciences Inc. (the “Company”) shall receive the following compensation for their service as members of the Board of Directors of the Company (the “Board”).

Director Compensation

Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract and retain outstanding director candidates and reflects the substantial time commitment necessary to oversee the Company’s affairs. We also seek to align the interests of our directors and our stockholders, and we have chosen to do so by compensating our non-employee directors with a mix of cash and equity-based compensation.

Cash Compensation

The fees that will be paid to our non-employee directors for service on the Board, and for service on each committee of the Board on which the director is then a member, and the fees that will be paid to the chairperson of each committee of the Board will be as follows:

…

HSBC INSTITUTIONAL TRUST SERVICES (SINGAPORE) LIMITED AS TRUSTEE OF CAPITALAND ASCENDAS REIT

and

AMBIQ MICRO SINGAPORE PRIVATE LTD.

Lease for

10 KALLANG AVENUE

#14-10 TO #14-13 APERIA

SINGAPORE 339510

---

SCHEDULE 1 DETAILS OF LEASE

Item 1:	Landlord (we, us, our)	:	HSBC INSTITUTIONAL TRUST SERVICES (SINGAPORE) LIMITED AS TRUSTEE OF CAPITALAND ASCENDAS REIT
Item 2:	Tenant (you, your)	:	AMBIQ MICRO SINGAPORE PRIVATE LTD.
Item 3:	Premises
	(a) Unit numbers	:	#14-10 to #14-13 Aperia
	(b) Building	:	10 Kallang Avenue Aperia Singapore 339510
	(c) Boundary	:	(for identification only) edged in red in the attached plan (or plans), marked as schedule 5
Item 4:	Floor Area	:
	Unit numbers #14-10 to #14-13 Aperia Total Floor Area		Floor Area (square metre) 875.45 875.45
Item 5:	Possession Date	:	15 January 2026
Item 6:	Start Date	:	15 March 2026

…

EXCLUSIVE LICENSE AGREEMENT

This  Exclusive License Agreement (this “Agreement”) is effective as of March 15, 2026 (the “Effective Date”) and made and entered into on May 8, 2026 (the “Execution Date”), by and between Impetis Biosciences Limited, a company incorporated in India, having a place of business at address of 6th Floor, Wing E, Times Square, Marol, Andheri-Kurla Road, Gamdevi, Andheri-East, Mumbai, 400059, Maharashtra, India (“Licensor”), and Vyome Holdings, Inc., a Delaware corporation having its principal office at Harvard Square One Mifflin Place, Suite 400, Cambridge, MA 02138 (the “Licensee” and together, with the Licensor, the “Parties” and each a “Party”).

Recitals

WHEREAS, Licensor is in the business of progressing its high-value assets through collaborations and partnerships in order to transform the lives of patients suffering from diseases that have no or limited therapeutic choices;

…

Exhibit 10.6

AMENDMENT NO. 2 TO CONSULTING AGREEMENT

This AMENDMENT NO.2 (“Amendment No. 2”) to the CONSULTING AGREEMENT dated April 11, 2024 and amended November 21, 2024 (the “Agreement”) between OPUS GENETICS INC., a Delaware corporation having its principal place of business at 8 Davis Drive, Durham, NC, 27713 (the “Company”), and JAY S. PEPOSE MD, whose address is 1125 Templeton Place, Chesterfield, MO 63017 (“Consultant”) is made as of April 10, 2026 (the “Effective Date”).

I.The term of the Agreement shall be extended to May 11, 2026.

II.All other terms of the Agreement remain in effect without change.

Having understood and agreed to the foregoing, the Company and Consultant have signed this Amendment No.2 and the same shall be effective as of the Effective Date.

IN WITNESS WHEREOF, the parties have, by duly authorized persons, executed this Agreement as of the Effective Date.

…